Whole cell vaccines - Past progress and future strategies

Seminars in Oncology

Volumn 39, Issue 3, 2012, Pages 276-286

  Keenan, Bridget P ^a,b   Jaffee, Elizabeth M ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BEVACIZUMAB; CANCER VACCINE; CD20 ANTIBODY; CD40 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; OX40 LIGAND; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; WHOLE CELL VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE CHECKPOINT; COMPLEMENT DEPENDENT CYTOTOXICITY; DENDRITIC CELL; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; METASTATIC MELANOMA; MULTIMODALITY CANCER THERAPY; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TRANSGENIC MOUSE; TUMOR CELL; WHOLE BODY RADIATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84861164690     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.02.007     Document Type: Article

References (69)

1. J. Simons, E. Jaffee, C. Weber Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer Cancer Res 57 1997 1537 1546 (Pubitemid 27175572)
2. M.C. Thomas, T.F. Greten, D.M. Pardoll, E.M. Jaffee Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine Hum Gene Ther 9 1998 835 843 (Pubitemid 28197370)
3. J. Nemunaitis, R.O. Dillman, P.O. Schwarzenberger Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer J Clin Oncol 24 2006 4721 4730 (Pubitemid 46630936)
4. A. Thomas, L. Santarsiero, E. Lutz Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients J Exp Med 200 2004 297 306 (Pubitemid 39031249)
5. G. Dranoff, E. Jaffee, A. Lazenby Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci U S A 90 1993 3539 3543 (Pubitemid 23111402)
6. R. Soiffer, T. Lynch, M. Mihm Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma Proc Natl Acad Sci U S A 95 1998 13141 13146
7. G. Dranoff GM-CSF-based cancer vaccines Immunol Rev 188 2002 147 154 (Pubitemid 35398872)
8. Jaffee E, Hruban R, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 200;19;145-56.
9. E. Lutz, C.J. Yeo, K.D. Lillemoe A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: a phase II trial of safety, efficacy, and immune activation Ann Surg 253 2011 328 335
10. D.T. Le, D.M. Pardoll, E.M. Jaffee Cellular vaccine approaches Cancer J 16 2010 304 310
11. H. Shirota, D.M. Klinman CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity Cancer Immunol Immunother 60 2011 659 669
12. A.D. Sandler, H. Chihara, G. Kobayashi CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma Cancer Res 63 2003 394 399 (Pubitemid 36152498)
13. K. Hiraoka, S. Yamamoto, S. Otsuru Enhanced tumor-specific long-term immunity of hemagglutinating virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides J Immunol 173 2004 4297 4307 (Pubitemid 39280657)
14. Y.M. Murad, T.M. Clay CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer BioDrugs 23 2009 361 375
15. N. Larmonier, M. Marron, Y. Zeng Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10 Cancer Immunol Immunother 56 2007 48 59 (Pubitemid 44812446)
16. D.A. Thomas, J. Massagué TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance Cancer Cell 8 2005 369 380 (Pubitemid 41579832)
17. + regulatory T cells by TGF-beta induction of transcription factor Foxp3 J Exp Med 198 2003 1875 1886 (Pubitemid 38032120)
18. J. Olivares, P. Kumar, Y. Yu Phase I trial of TGF-{beta}2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine Clin Cancer Res 17 2011 183 192
19. H. Fakhrai, J.C. Mantil, L. Liu Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma Cancer Gene Ther 13 2006 1052 1060 (Pubitemid 44760103)
20. S.M. Jensen, L.D. Maston, M.J. Gough Signaling through OX40 enhances antitumor immunity Semin Oncol 37 5 2010 Oct 524 532
21. D. Hirschhorn-Cymerman, G.A. Rizzuto, T. Merghoub OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis J Exp Med 206 2009 1103 1116
22. + Th cell antitumor immunity in mice J Clin Invest 117 2007 3330 3338 (Pubitemid 350096989)
23. + T cell tolerance to an endogenous tumor antigen J Immunol 176 2006 974 983 (Pubitemid 43099696)
24. C. Cuadros, A.L. Dominguez, P.L. Lollini Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice Int J Cancer 116 2005 934 943 (Pubitemid 41209201)
25. E. Fonsatti, M. Maio, M. Altomonte, P. Hersey Biology and clinical applications of CD40 in cancer treatment Semin Oncol 37 2010 517 523
26. M.R. Sorensen, P.J. Holst, M.A. Steffensen, J.P. Christensen, A.R. Thomsen Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model Vaccine 28 2010 6757 6764
27. J. Rüter, S.J. Antonia, H.A. Burris, R.D. Huhn, R.H. Vonderheide Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors Cancer Biol Ther 10 2010 983 993
28. S. Dessureault, D. Noyes, D. Lee A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease Ann Surg Oncol 14 2007 869 884 (Pubitemid 46175338)
29. G.L. Beatty, E.G. Chiorean, M.P. Fishman CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans Science 331 2011 1612 1616
30. F. Orlandi, F.M. Venanzi, A. Concetti Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine Clin Cancer Res 13 2007 6195 6203 (Pubitemid 350075081)
31. R.T. Reilly, J.P. Machiels, L.A. Emens The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors Cancer Res 61 2001 880 883 (Pubitemid 32174395)
32. + T cell effector function and tumor-free survival in Her-2/neu-transgenic mice J Immunol 171 2003 2161 2169 (Pubitemid 36966500)
33. P. Kim, T. Armstrong, H. Song Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs J Clin Invest 118 2008 1700 1711 (Pubitemid 351632374)
34. M. Jinushi, F.S. Hodi, G. Dranoff Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity Proc Natl Acad Sci U S A 103 2006 9190 9195 (Pubitemid 43902554)
35. R.L. Ferris, E.M. Jaffee, S. Ferrone Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape J Clin Oncol 28 2010 4390 4399
36. J.M. Roda, R. Parihar, C. Magro, G.J. Nuovo, S. Tridandapani, W.E. Carson 3rd Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells Cancer Res 66 2006 517 526 (Pubitemid 43166061)
37. J. Schoenfeld, M. Jinushi, Y. Nakazaki Active immunotherapy induces antibody responses that target tumor angiogenesis Cancer Res 70 2010 10150 10160
38. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
39. E.A. Manning, J.G. Ullman, J.M. Leatherman A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism Clin Cancer Res 13 2007 3951 3959 (Pubitemid 47037603)
40. D.I. Gabrilovich, T. Ishida, S. Nadaf, J.E. Ohm, D.P. Carbone Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function Clin Cancer Res 5 1999 2963 2970 (Pubitemid 29493976)
41. M.L. Salem, D.J. Cole Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination Cancer Immunol Immunother 59 2010 341 353
42. J. Ma, W.J. Urba, L. Si, Y. Wang, B.A. Fox, H.M. Hu Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution Eur J Immunol 33 2003 2123 2132 (Pubitemid 37010029)
43. S.A. Rosenberg, J.C. Yang, R.M. Sherry Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy Clin Cancer Res 17 2011 4550 4557
44. L. Apetoh, F. Ghiringhelli, A. Tesniere Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nat Med 13 2007 1050 1059 (Pubitemid 47517504)
45. O. Micheau, E. Solary, A. Hammann, F. Martin, M.T. Dimanche-Boitrel Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity J Natl Cancer Inst 89 1997 783 789 (Pubitemid 27242279)
46. J. Li, A.V. King, S.L. Stickel Whole tumor cell vaccine with irradiated S180 cells as adjuvant Vaccine 27 2009 558 564
47. U.K. Liyanage, T.T. Moore, H.G. Joo Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with breast or pancreas adenocarcinomas J Immunol 169 2002 2756 2761 (Pubitemid 34921025)
48. R. Liu, S. Xiong, L. Zhang, Y. Chu Enhancement of antitumor immunity by low-dose total body irradiation is associated with selectively decreasing the proportion and number of T regulatory cells Cell Mol Immunol 7 2010 157 162
49. A.M. Ercolini, B.H. Ladle, E.A. Manning Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response J Exp Med 201 2005 1591 1602 (Pubitemid 40723662)
50. J.P. Machiels, R.T. Reilly, L.A. Emens Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice Cancer Res 61 2001 3689 3697 (Pubitemid 32694981)
51. S. Viaud, C. Flament, M. Zoubir Cyclophosphamide induces differentiation of Th17 cells in cancer patients Cancer Res 71 2011 661 665
52. D. Laheru, E. Lutz, J. Burke, B. Biedrzycki, S. Solt, B. Onners Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation Clin Cancer Res 14 2008 1455 1463 (Pubitemid 351413929)
53. G. Chong, M.A. Morse Combining cancer vaccines with chemotherapy Expert Opin Pharmacother 6 2005 2813 2820 (Pubitemid 43009544)
54. J. Vincent, G. Mignot, F. Chalmin 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity Cancer Res 70 2010 3052 3061
55. H.S. Kim, H.M. Park, J.S. Park Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model Vaccine 28 2010 7787 7796
56. K.N. Kodumudi, K. Woan, D.L. Gilvary, E. Sahakian, S. Wei, J.Y. Djeu A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers Clin Cancer Res 16 2010 4583 4594
57. L.W. Pfannenstiel, S.S. Lam, L.A. Emens, E.M. Jaffee, T.D. Armstrong Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice Cell Immunol 263 2010 79 87
58. R.A. Prell, L. Gearin, A. Simmons, M. Vanroey, K. Jooss The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration Cancer Immunol Immunother 55 2006 1285 1293 (Pubitemid 43992054)
59. L.A. Emens, J.M. Asquith, J.M. Leatherman Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation J Clin Oncol 27 2009 5911 5918
60. J.J. Engelhardt, T.J. Sullivan, J.P. Allison CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism J Immunol 177 2006 1052 1061 (Pubitemid 44036607)
61. + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer Proc Natl Acad Sci U S A 107 2010 7875 7880
62. A. van Elsas, A.A. Hurwitz, J.P. Allison Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation J Exp Med 190 1999 355 366 (Pubitemid 29374833)
63. S.A. Quezada, K.S. Peggs, M.A. Curran, J.P. Allison CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells J Clin Invest 116 2006 1935 1945 (Pubitemid 44033317)
64. F.S. Hodi, S.J. O'Day, D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
65. F.S. Hodi, M.C. Mihm, R.J. Soiffer Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci U S A 100 2003 4712 4717 (Pubitemid 36457795)
66. J.R. Brahmer, C.G. Drake, I. Wollner Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 28 2010 3167 3175
67. B. Li, M. VanRoey, C. Wang, T.H. Chen, A. Korman, K. Jooss Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors Clin Cancer Res 15 2009 1623 1634
68. S.F. Ngiow, B. von Scheidt, H. Akiba, H. Yagita, M.W. Teng, M.J. Smyth Anti-TIM3 antibody promotes T cell IFN-{gamma}-mediated anti-tumor immunity and suppresses established tumors Cancer Res 71 2011 3540 3551
69. J.F. Grosso, C.C. Kelleher, T.J. Harris LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems J Clin Invest 117 2007 3383 3392 (Pubitemid 350096994)